[The case of rofecoxib(Vioxx)-what do we learn from this case].
Vuorenkoski
Lauri
L
lauri.vuorenkoski@stakes.fi
D004345:Drug Industry; D005387:Finland; D006801:Humans; D007400:Interprofessional Relations; D007783:Lactones / Q000009:adverse effects* / Q000627:therapeutic use; D010353:Patient Education as Topic; D010818:Practice Patterns, Physicians'; D018570:Risk Assessment; D013450:Sulfones / Q000009:adverse effects* / Q000627:therapeutic use
D007783:Lactones; D013450:Sulfones; C116926:rofecoxib